



# ISEV EVS IN CARDIOVASCULAR RESEARCH ABSTRACT SUBMISSION GUIDELINES

## Key Dates:

<b>Abstract Launch</b>	July 8, 2026
<b>Abstract Close</b>	September 9, 2026
<b>Author Notifications</b>	October 2, 2026
<b>Presenting Author Registration Deadline</b>	October 16, 2026

## ISEV invites abstracts across these five tracks:

- 1. EVs in Cardiometabolic Vascular Inflammation:** EV-generation and EV-mediated signaling in vascular dysfunction, immune activation and interorgan cross-talk in cardiometabolic diseases.
- 2. Cardiac Injury & Repair:** Role of cardiomyocyte, fibroblast, endothelial and stem cell EVs in myocardial healing, stroke and traumatic brain injury.
- 3. EV biomarkers & Liquid Biopsy in CVD:** Advances in CVD proteomic/miRNA/lipidomic and integrated EV signatures for early detection.
- 4. EV Engineering & Therapeutics:** Engineered EVs, drug delivery and scaling and safety.
- 5. Imaging Techniques and EV Assessment In Vivo:** Super-resolution EV imaging and translational approaches.

**Abstracts are welcome from across the ecosystem:** Academic researchers, technology developers, biotech and pharma scientists, clinical investigators, regulatory and translational specialists, and trainees entering the EV field. ISEV CVR will be the inaugural international meeting dedicated to EVs in cardiovascular science. It will bring together a global, interdisciplinary community to present cutting-edge research, shape translational strategies, and catalyse cross-sector collaboration.

## Submission Guidelines

1. Please consult the [Minimal Information for Studies of EVs \(MISEV2023\)](#) and ensure that your abstract is responsive to the guidelines, including on nomenclature, sample processing, separation, characterization, functional studies, and reporting.
2. The title of the abstract should not exceed 210 characters, and the main body of the abstract should not exceed 2,000 characters.
3. The submission portal will include separate categories for Introduction, Methods, Results, and Summary/Conclusions. Please organize your abstract according to this structure.
4. Capitalize only the first letter of the first word of the title (unless for abbreviations or proper nouns) and do not end the title with a period ("."). Do not include quotation marks.

5. The abstract must contain primary scientific or clinical data that has not been published elsewhere and has not been presented previously at an ISEV meeting. Do not partition results from the same study into multiple abstracts, and do not submit a copy or close copy of an abstract under more than one theme.
6. The abstract submitter is responsible for ensuring that all authors have read the abstract and agreed to be coauthors.
7. Clearly indicate molecular findings with consensus names, not generic identifiers like “Protein X” and “miRNA Y”. Abstracts without these details may be rejected. Please note if a patent is pending and therefore limiting information disclosure.
8. Submitted abstracts on human subjects must have ethical approval and state whether informed consent was obtained. Animal studies need to be approved by the relevant animal use committees.
9. If off-label/unlicensed use of drugs was involved in the study, please state this clearly.
10. The abstract title and text may not contain trade names. ISEV reserves the right to replace trade names in accepted abstracts.
11. Abstracts should be submitted in English.
12. Choose the preferred presentation mode: oral, poster or “lightning” talk. Presentations will be selected for oral presentation, poster presentation, and/or poster “lightning” talks.

#### **Withdrawal Policy**

To withdraw an accepted abstract from presentation or publication, send an e-mail to ISEV ([contact@isev.org](mailto:contact@isev.org)) before **October 16, 2026**. All abstracts will be prepared for publication in The Journal of Extracellular Vesicles. Withdrawn abstracts cannot be presented or published.